Biogen is a Massachusetts-based biotechnology company that researches and develops novel therapies for the treatment of neurological diseases across the globe.
There are more than 6.000 identified rare diseases1 and for over 90%, no approved treatment exists today.2 Rare diseases require long-term dedication.At Biogen, working in rare diseases isn’t just a moment in time — it’s a commitment. One driven by science, collaboration and profound respect for the communities we serve.Today, we recognise all the people whose expertise and passion help drive progress in the rare disease field.#RareDiseaseDay #RareButMany #ShareYourColours1. Nguengang Wakap, S. ...
New Alzheimer's drugs aim for cure rather than just delaying progression. Researchers target tau protein and explore repurposing cancer drugs. Early diagnosis and safer treatments are priorities.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.